Dr. Bastholt on Lenvatinib in Thyroid Cancer

Lars Bastholt, MD
Published: Tuesday, Mar 07, 2017



Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.

Lenvatinib, a TKI that targets VEGFR1-3, FGFR1-4, PDGFR-α, RET, and c-KIT, is currently being investigated as first-line therapy in several clinical trials, and the preferred first-line treatment for thyroid cancer in countries such as Denmark. Efficacy data published in 2014 showed that this agent increased progression-free survival greatly, as compared to other TKIs.

Future treatment for rarer cancers such as this should be left up to specialists, says Bastholt, as these types of agents should be introduced in a centralized fashion with close evaluation.
 


Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.

Lenvatinib, a TKI that targets VEGFR1-3, FGFR1-4, PDGFR-α, RET, and c-KIT, is currently being investigated as first-line therapy in several clinical trials, and the preferred first-line treatment for thyroid cancer in countries such as Denmark. Efficacy data published in 2014 showed that this agent increased progression-free survival greatly, as compared to other TKIs.

Future treatment for rarer cancers such as this should be left up to specialists, says Bastholt, as these types of agents should be introduced in a centralized fashion with close evaluation.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x